Literature DB >> 19432886

Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa.

Tomomitsu Tahara1, Tomoyuki Shibata, Hiromi Yamashita, Masakatsu Nakamura, Daisuke Yoshioka, Masaaki Okubo, Ichiro Hirata, Tomiyasu Arisawa.   

Abstract

There have been reports showing a protective role of nonsteroidal anti-inflammatory drugs (NSAIDs) against gastrointestinal cancers. CpG island hyper methylation (CIHM) of tumor suppressor genes is a major event in carcinogenesis. We investigated the CIHM status of non-cancerous gastric mucosa in chronic NSAID users and non-users and assessed the effect of NSAIDs on CIHM. Gastric mucosa samples were obtained from 51 chronic NSAID users and 180 non-users. CIHM of p14(ARF), p16(INK4a), death-associated protein kinase (DAP-kinase), and E-cadherin (CDH1) genes were determined by methylation-specific PCR. CIHM high was defined as two or more CpG islands methylated. CIHM of p14, p16, CDH1, and CIHM high were lower in chronic NSAID users than in non-users (p14: non-users vs users = 32.2%vs 9.8%, P = 0.003; p16: non-users vs users = 35.0%vs 15.7%, P = 0.02; CDH1: non-users vs users = 36.1%vs 9.8%, P = 0.0009; CIHM high: non-users vs users = 44.4%vs 17.6%, P = 0.0009). NSAID use was also associated with decreased number of CIHM by anova (R = -0.32, P < 0.0001). Multivariate logistic regression analysis with adjustment for sex, age, Helicobacter pylori infection, and NSAID use revealed that NSAID use was inversely correlated with all four CIHM and CIHM high as an independent factor (p14: odds ratio [OR] = 0.17, 95% confidence interval [CI] = 0.06-0.48; p16: OR = 0.32, 95% CI = 0.14-0.75; DAP-kinase: OR = 0.45, 95% CI = 0.22-0.92; CDH1: OR = 0.18, 95% CI = 0.06-0.48; CIHM high: OR = 0.21, 95% CI = 0.09-0.49). No association was found between CIHM status and the duration or dose of NSAIDs. Chronic NSAID use suppresses CIHM in human gastric mucosa. NSAIDs may have a suppressive role against methylation-related gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432886     DOI: 10.1111/j.1349-7006.2009.01175.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  NSAIDs and Colorectal Cancer Control: Promise and Challenges.

Authors:  George J Tsioulias; Mae F Go; Basil Rigas
Journal:  Curr Pharmacol Rep       Date:  2015-05-14

Review 2.  Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2014-07-05       Impact factor: 6.730

3.  Non-Steroidal Anti-Inflammatory Drug Use and Genomic DNA Methylation in Blood.

Authors:  Lauren E Wilson; Sangmi Kim; Zongli Xu; Sophia Harlid; Dale P Sandler; Jack A Taylor
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

Review 4.  E-cadherin and gastric cancer: cause, consequence, and applications.

Authors:  Xin Liu; Kent-Man Chu
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

5.  DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis.

Authors:  Hagar Taman; Christopher G Fenton; Endre Anderssen; Jon Florholmen; Ruth H Paulssen
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

6.  Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer.

Authors:  Yanyun Ma; Chunxia Wang; Mengqi Shi; Mingshan Li; Lin Li; Tuanjie Che; Jing Qu
Journal:  Mol Clin Oncol       Date:  2022-09-02

7.  Genome-wide DNA Methylation in Treatment-naïve Ulcerative Colitis.

Authors:  Hagar Taman; Christopher G Fenton; Inga V Hensel; Endre Anderssen; Jon Florholmen; Ruth H Paulssen
Journal:  J Crohns Colitis       Date:  2018-11-15       Impact factor: 9.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.